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KEY	POINTS	
• Adrenocortical	carcinoma	(ACC)	is	a	rare	cause	of	Cushing’s	syndrome	
• Prompt	diagnosis	and	treatment	are	important	due	to	its	very	aggressive	behavior.		Clinical	 presentation	 of	 Cushing’s	 syndrome	 may	 be	 atypical	 due	 to	 cancer-related	signs.	
• The	 biochemical	 hallmarks	 of	 Cushing’s	 syndrome	 caused	 by	 ACC	 are	 ACTH-independent	 hypercortisolism	 and	 frequent	 concomitant	 hypersecretion	 of	 other	steroids	(precursors	and/or	androgens)		
• The	radiological	phenotype	of	ACC	on	the	CT	scan	features	its	large	size,	high	density,	intra-tumoral	necrosis.		
• Surgery	 is	 the	 treatment	 of	 choice	 and	 should	 be	 attempted	 whenever	 a	 radical	resection	is	feasible.		
• ACC	has	a	high	propensity	to	recur	and	for	this	reason	post-operative	adjuvant	therapy	with	mitotane	is	used,	particularly	when	adverse	prognostic	factors	are	present.		
• Tumor	 stage,	 positive	 resection	 margins,	 high	 proliferation	 activity,	 and	hypercortisolism	are	associated	with	a	worse	prognosis.	
• Hypercortisolism	should	be	promptly	corrected	by	using	mitotane	in	combination	with	other	inhibitors	of	steroidogenesis	(i.e.	Metyrapone).				
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SYNOPSIS	
Adrenocortical	 carcinoma	 (ACC)	 is	 a	 rare	 and	 aggressive	 tumor.	 ACC	may	 be	 associated	 to	different	syndromes	of	hormone	excess,	most	frequently	Cushing's	syndrome	with	or	without	hypersecretion	of	androgens.	Recent	data	suggest	that	cortisol	excess	is	a	negative	prognostic	factor,	both	in	advanced	and	localized	ACC.	Surgery	with	radical	intent,	when	feasible,	 is	the	most	effective	treatment	for	ACC	with	hypercortisolism.	Mitotane	is	the	medical	treatment	of	choice,	both	postoperatively	and	 in	 inoperable	or	metastatic	 cases.	Due	 to	 its	 slow	onset	of	action,	combination	with	other	anti-secretory	agents	(i.e.	metyrapone)	is	helpful	to	achieve	a	more	rapid	and	effective	control	of	hypercortisolism.	
INTRODUCTION	
	Adrenocortical	 carcinoma	 (ACC)	 is	 a	 rare	 and	 aggressive	 tumor	 with	 an	 annual	 incidence	between	0.7	and	2	 cases	per	million.	ACC	 is	more	 frequently	detected	 in	women	 (55–60%)	and	certain	age	groups	(fourth	and	fifth	decades);	however,	ACC	can	occur	at	any	age1.	ACC	can	affect	children,	with	an	exceedingly	high	incidence	reported	in	southern	Brazil,	due	to	the	high	 prevalence	 of	 a	 TP53	 germline	 mutation2.	 ACCs	 most	 frequently	 present	 as	 sporadic	tumors,	 but	 can	 be	 encountered	 in	 the	 setting	 of	 hereditary	 tumor	 syndromes,	 such	 as	 Li	Fraumeni	 (TP53	 germline	 and	 somatic	mutations),	 familial	 adenomatous	 polyposis	 coli	 (β-catenin	somatic	mutations)	and	Beckwith–Wiedeman	(IGF-2	overexpression)3.	Patients	 with	 ACC	 have	 an	 extremely	 poor	 prognosis,	 with	 an	 overall	 5-year	 survival	 rate	between	16	 and	47%4.	Prognosis	 is	mainly	 influenced	by	 completeness	of	 surgical	 removal	and	tumor	stage	at	diagnosis,	with	a	5-year	stage-dependent	survival	of	81,	61,	50,	and	13	%,	respectively,	from	stage	1	to	stage	45.	However,	ACC	is	a	heterogeneous	disease	with	variable	survival	at	any	stage	depending	on	molecular,	pathological	and	clinical	factors	that	have	only	been	 partially	 ellucidated6.	 One	 of	 the	 factors	 influencing	 the	 clinical	 phenotype	 of	 ACC	patients	 is	 the	 functional	 activity	 of	 the	 tumor,	 which	 may	 result	 in	 different	 endocrine	syndromes3,4,6.	Manifestations	of	adrenal	steroid	hormone	excess	represent	the	most	common	presentation	 of	 ACC	 in	 up	 to	 60%	 of	 cases4	 (Figure	 1).	 Patients	with	 non-functioning	 ACC	present	with	 back	 or	 abdominal	 pain,	 nausea,	 vomiting,	 or	 less	 frequently	 fever	 and	weigh	loss.	Also,	in	an	increasing	number	of	patients,	ACC	is	discovered	serendipitously,	due	to	the	widespread	application	of	high-resolution	cross-sectional	scans7. 	
	
	
	
	
CLINICAL	PRESENTATION	ACC	has	the	propensity	to	produce	and	secrete	steroids;	thus,	in	all	patients	with	a	suspected	ACC,	 signs	 and	 symptoms	 of	 cortisol,	 aldosterone,	 and	 sex	 steroids	 should	 be	 actively	investigated4	(Box	1).	Concomitant	secretion	of	different	steroids	 is	a	hallmark	of	ACC.	Pure	estrogen	excess	 is	rare	and	may	cause	gynecomastia,	 loss	of	 libido	and	testicular	atrophy	in	men8.		Patients	 with	 cortisol-secreting	 ACC	 exhibit	 facial	 plethora,	 easy	 bruising,	 weight	 gain,	proximal	myopathy,	severe	hypertension	and	uncontrolled	diabetes	mellitus.	Hypokalemia	is	common	with	severe	hypercortisolism	because	mineralocorticoid	receptors	are	triggered	by	the	large	amount	of	cortisol	that	overwhelms	the	inactivating	capacity	of	corticosteroid	11β-dehydrogenase	isoenzyme	2	(HSD11B2).	Women	frequently	complain	of	acne,	hirsutism,	and	oligomenorrhea4.	The	differential	diagnosis	in	these	situations	is	PCOS,	especially	with	mild	or	subclinical	 hypercortisolism.	 Clinical	 clues	 that	 are	 helpful	 to	 the	 diagnosis	 of	 ACC	 are	 the	concomitant	 existence	 of	 Cushingoid	 phenotype	 with	 signs	 of	 marked	 androgen	 excess,	 or	Cushing	 phenotype	 along	 with	 cancer-related	 symptoms	 (anorexia,	 cachexia,	 mass	 effect).	With	rapidly	growing	tumors,	cancer-related	features	dominate	the	clinical	presentation.	ACC	can	also	cause	deep	venous	thrombosis	or	pulmonary	embolism	due	to	either	cortisol	excess	or	malignancy4.	Cortisol	excess	should	be	excluded	in	all	patients	with	suspected	ACC,	even	if	they	don’t	harbor	typical	cushingoid	features9.	Specific	findings	at	CT	scan,	such	as	large	mass	size,	high	density	(>10	Hounsfield	Units),	intra-tumoral	necrosis,	irregular	shape	and	margins	should	raise	the	suspect	of	an	ACC	(Figure	2).	
	
	
	
	
Box	1.	Clinical	manifestations		
• Concomitant	secretion	of	multiple	steroids	is	a	hallmark	of	ACC	
• Hypercortisolism	 in	 the	 most	 frequent	 endocrine	 abnormality	 in	 ACC,	 although	 can	present	with	catabolic	features	due	to	rapidly	progressive	malignancy	
• Manifestations	of	hypercortisolism	 in	ACC	 can	be	mild	or	 subclinical,	 and	erroneously	attributed	of	PCOS		
• Flank	pain	and	constitutive	symptoms	are	frequent	in	“incidental”	ACC	
ENDOCRINE	ASSESSMENT A	detailed	hormonal	work-up	 (Table	 1)	 should	be	performed	preoperatively	 in	all	patients	with	suspected	ACC	for	the	following	reasons:		i) Demonstration	of	hypersecretory	steroid	profile	establishes	the	adrenocortical	origin	of	 the	tumor,	while	other	differential	diagnoses	are	being	ruled	out	(i.e.	lymphoma,	sarcoma);	ii) The	 steroid	 profile	may	 be	 helpful	with	 evaluation	 of	 the	malignant	 potential	(i.e.	 estradiol	 excess	 in	males,	 high	 concentration	 of	 dehydroepiandrosterone	sulphate	–DHEAS-	or	steroid	precursors);		iii) Presence	of	autonomous	cortisol	secretion	in	a	patient	with	ACC	indicates	a	risk	of	 post-operative	 adrenal	 insufficiency,	 which	 can	 be	 potentially	 life-threatening;		iv) Demonstration	of	steroid	excess	at	baseline	establishes	tumor	markers	that	can	be	useful	to	detect	persistence	or	recurrence	of	disease	postoperatively	4,8.		In	patients	without	overt	steroid	overproduction,	ACC	may	still	secrete	excessive	amounts	of	adrenal	steroid	precursors	due	 to	decreased	expression	of	several	steroidogenic	enzymes10.	Increased	secretion	of	urinary	metabolites	of	several	steroids,	and	precursors	of	androgens,	glucocorticoids	 or	 mineralcorticoids	 can	 be	 detected	 even	 in	 the	 absence	 of	 a	 clinically	 or	biochemically	 overt	 steroid	 excess	 by	 the	 use	 of	 sensitive	 methods	 such	 as	 gas	chromatography/mass	spectrometry.	When	applying	this	methodology,	more	than	95%	of	all	patients	with	ACC	were	found	to	secrete	autonomously	steroids	or	steroid	precursors11.		A	 standard	 1	 mg	 overnight	 dexamethasone	 test	 (1-mg	 DST)	 is	 recommended	 to	 exclude	hypercortisolism	in	ACC,	similar	with	adrenal	 incidentaloma.	This	test	has	higher	sensitivity	(95%	at	 a	 cortisol	 threshold	of	1.8	μg/dL),	 compared	with	24-h	urinary-free	 cortisol	 (UFC)	which	is	not	helpful	 in	cases	of	mild	hypercortisolism12.	 If	cortisol	 levels	 following	the	1-mg	
DST	are	not	suppressed	despite	lack	of	overt	Cushing	phenotype,	the	condition	of	autonomous	cortisol	 secretion	 may	 be	 present.	 The	 recent	 guidelines	 of	 the	 European	 Society	 of	Endocrinology	 and	 the	 European	 Network	 for	 the	 Study	 of	 Adrenal	 Tumors	 (ENSAT)	promoted	 this	 definition	 to	 the	 classic	 “subclinical	 Cushing’s	 syndrome”9.	 Autonomous	cortisol	secretion	 is	certain	 for	a	cortisol	 levels	above	5	μg/dL	after	1-mg	DST,	while	values	between	 1.8	 μg/dL	 and	 5	 μg/dL	 require	 additional	 investigation	 to	 confirm	 the	 diagnosis.	These	 include	 plasma	 ACTH	 and	 UFC	 levels	 as	 well	 as	 a	 thorough	 evaluation	 of	 clinical	conditions	 potentially	 associated	 with	 cortisol	 excess	 (i.e.	 arterial	 hypertension,	 diabetes,	obesity).	Recognizing	asymptomatic	cortisol	excess	preoperatively	identifies	the	patients	who	benefit	from	glucocorticoid	replacement	after	adrenalectomy13.		Aldosterone-producing	ACC	is	rare	and	is	generally	associated	with	severe	hypertension	and	marked	 hypokalemia14.	 Screening	 for	 hyperaldosteronism	 by	 measuring	 of	 plasma	aldosterone	and	plasma	renin	activity	(PRA)	(or	direct	renin	concentration)	is	recommended	in	 all	 hypertensive	 and/or	 hypokalemic	 patients	 with	 adrenal	 masses15.	 In	 some	 cases,		pseudo-aldosteronism	is	present,	due	to	increased	production	of	deoxycorticosterone	.	Hypersecretion	 of	 sexual	 steroids	 is	 frequently	 observed	 in	 ACC	 patients.	 Estrogens	 excess	should	 be	 ascertained	 in	males	 (especially	 in	 cases	 of	 gynecomastia)	 and	 post-menopausal	females.	 Baseline	 17-OH	 progesterone	 levels	 are	 frequently	 increased,	 as	 well	 as	androstenedione	 and	 DHEAS,	 which	 leads	 to	 increased	 plasma	 testosterone	 in	 females4.	Measurement	 of	 steroid	 precursors	 in	 blood	 or	 urine	 may	 be	 exploited	 for	 diagnostic	purposes.	However,	the	value	of	increased	DHEAS	levels	to	predict	malignancy	of	an	adrenal	mass	is	rather	low16.	More	recently,	it	was	demonstrated	that	serum	steroid	paneling	by	LC-MS/MS	 is	a	useful	 tool	 to	discriminate	ACC	 from	other	adrenal	 tumor	 lesions.	 In	 this	 study,	both	 the	number	of	 steroids	 secreted	 in	high	 amounts	 and	 the	marked	elevation	of	 several	steroid	intermediates	without	biological	activity	was	characteristic	of	ACC	and	useful	for	the	
differential	 diagnosis.	 The	 cortisol	 precursor	 11-deoxycortisol	 was	 found	 the	 most	discriminating	between	ACC	and	non-ACC	adrenal	lesions17.	Assessment	 of	 plasma	 or	 urine	 fractionated	metanephrines	 is	 recommend	 in	 patients	with	suspected	 ACC	 to	 exclude	 a	 pheochromocytoma,	 and	 avoid	 misdiagnosis	 and	 unexpected	intraoperative	 complications4,7,9.	 Pertinently,	 a	 pheochromocytoma	 may	 appear	 as	 a	 large,	heterogeneous	and	hypervascularized	mass	mimicking	ACC.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
TABLE	1.	Endocrine	assessment	in	patients	with	suspected	or	proven	ACC	
 
CONDITION 
 
 
TESTS 
 
CORTISOL EXCESS 
 
Serum cortisol following 1-mg DST  
 
If >1.8 mcg/dL: 
Urinary free cortisol (24 h collection) 
Morning plasma ACTH  
Night-time salivary cortisol 
 
ALDOSTERONE EXCESS 
 
Serum potassium 
 
If hypokalemia and/or arterial hypertension: 
Plasma aldosterone and plasma renin activity (PRA) or direct 
renin  
 
SEX STEROID EXCESS 
 
Androstenedione 
Testosterone 
 
17β-estradiol (in men and postmenopausal women) 
 
STEROID PRECURSORS EXCESS 
 
DHEAS 
17OH-progesterone 
 
CATHECOLAMINE EXCESS 
 
Urinary fractionated metanephrines (24 h collection) or free 
plasma metanephrines  
 	
 
PROGNOSTIC	FACTORS		ACC	 stage	 and	 a	 margin-free	 resection	 are	 important	 and	 validated	 prognostic	 factors3,4.		Currently,	 the	 ENSAT	 staging	 system	 is	 the	 most	 frequently	 used	 and	 allows	 a	 clear	stratification	of	prognosis	by	stage.	In	particular,	a	5-year	stage-dependent	survival	of	81,	61,	50,	and	13%,	respectively,	from	stage	1	to	stage	4	has	been	demonstrated5	Since	surgery	still	represents	 the	 only	 curative	 treatment	 for	 ACC,	 an	 incomplete	 resection	 results	 in	 shorter	survival	within	the	same	stage3-5	.Resection	status	Rx	(unknown),	R1	(microscopically	positive	margins)	 and	 R2	 (macroscopically	 positive	 margins)	 are	 associated	 with	 progressively	reduced	survival	 irrespectively	of	other	risk	 factors3-5	.	 It	has	been	recently	established	 that	the	proliferation	activity	of	the	tumor	influences	the	risk	of	recurrence	following	R0	surgery.	Assessment	of	the	proliferation	index	Ki-67	is	currently	used	to	assess	proliferation,	despite	some	problems	to	harmonize	immunohistochemical	readings	among	different	pathologists.	In	a	European	multicenter	study,	a	Ki-67	value	at	10%	was	found	to	separate	patients	at	good	or	worse	prognosis	with	a	hazard	ratio	of	recurrence	of	1.042	per	each	%	increase18		The	role	of	overt	cortisol	excess	as	a	negative	prognostic	factor	has	been	first	suggested	in	an	Italian	 study19,	 including	72	patients	with	metastatic	or	 locally	 advanced	ACC,	 submitted	 to	chemotherapy	with	etoposide,	doxorubicin,	and	cisplatin	plus	mitotane.	Patients	with	cortisol	hypersecretion	had	shorter	overall	survival,	both	in	univariate	and	multivariate	analysis	(HR:	0.64,	 0.42–0.97;	 P<	 0.04).	 This	 finding	 was	 confirmed	 by	 a	 French	 study20,	 including	 202	patients	with	ACC	at	different	stages.	In	this	large	series	from	a	single	endocrine	center,	135	patients	 presented	 with	 hypercortisolism,	 and	 multivariate	 analysis	 identified	 cortisol	overproduction	 as	 an	 independent	 prognostic	 factor	 associated	 with	 shorter	 survival	 (HR	3.90;	 P<	 0.0001).	 In	 this	 subgroup	 of	 patients	 with	 cortisol-secreting	 tumors,	 adjuvant	mitotane	 treatment	 had	 a	 positive	 effect	 on	 the	 risk	 of	 death	 (HR	0.40;	 P<	0.04).	However,	another	 study	 in	 124	 patients	 with	 metastatic	 ACC,	 did	 not	 find	 an	 association	 between	
cortisol	secretion	and	prognosis	21.	The	interaction	between	cortisol	excess	and	adjuvant	mitotane	therapy	has	been	investigated	by	 Berruti	 and	 colleagues22	 in	 a	 multicenter,	 retrospective	 series	 of	 524	 patients	 with	completely	 resected	 ACC,	 of	 whom	 197	 patients	 	 (37.6%)	 with	 overt	 Cushing’s	 syndrome.	After	adjustment	 for	sex,	age,	 tumor	stage	and	adjuvant	mitotane	 therapy,	hypercortisolism	remained	a	strong	independent	predictor	for	both	recurrence	(HR:	1.30,	1.04–2.62;	P=	0.02)	and	death	 (HR:	1.55,	1.15–2.09;	P=	0.004).	Efficacy	of	adjuvant	mitotane	 treatment	was	not	affected	 by	 the	 secretory	 status.	 The	 study	 did	 not	 provide	 information	 on	 the	 impact	 of	subclinical	Cushing	on	prognosis.			More	recently,	a	 study	carried	out	 in	US	surgical	 institutions23	demonstrated	an	association	between	 cortisol	 secretion	and	 risk	of	postoperative	 complications	 (HR:	2.25,	1.04-4.88;	p=	0.04).	Moreover,	 the	 study	confirmed	 that	hypercortisolism	was	an	 independent	prognostic	factors	associated	with	shorter	recurrence-free	survival	(HR:	2.05,	1.16-3.60;	p	0.01).		There	 are	 several	 possible	 underlying	mechanisms	 by	which	 excess	 cortisol	 influences	 the	prognosis	in	ACC	patients.	First,	hypercortisolism	is	associated	with	increased	morbidity	and	mortality24	which	complicates	the	management	of	ACC	patients	(Box	1).	Second,	although	an	association	between	cortisol	secretion	and	tumor	grading	has	not	been	demonstrated	so	far,	tumors	with	 cortisol	 production	may	 be	more	 aggressive.	 This	was	 supported	 by	 a	 French	study	 evaluating	 the	 role	 of	 SKG1	 protein	 expression	 in	 ACC25.	 SKG1	 is	 a	 glucocorticoid-inducible	 kinase	 involved	 in	 cell	 cycle	 progression,	 acting	 as	 an	 anti-apoptotic	 factor.	 The	study	 demonstrated	 an	 inverse	 association	 between	 SGK1	 expression	 and	 cortisol	overproduction25.	 Low	 SGK1	 protein	 level	was	 identified	 as	 a	 negative	 prognostic	 factor	 in	ACC	 patients,	 being	 associated	with	 reduced	OS	 (HR:	 2.0,	 1.24–3.24;	 P	 <	 0.005).	 Third,	 the	immunosuppressive	 effects	 of	 overt	 cortisol	 excess	 before	 surgery	 may	 favor	 the	development	of	ACC	micrometastases	and	recurrences.		
Of	 note,	 studies	 implicating	 hypercortisolism	 as	 a	 negative	 predictive	 factor	 were	retrospective	 and	 used	 variable	 methods	 used	 to	 confirm	 cortisol	 excess.	 However,	 they	suggest	 that	 cortisol	excess	 in	ACC	may	 identify	a	 cluster	of	patients	who	need	more	active	surveillance	and	treatment	(Figure	3).		
	
Box	2.	Implications	of	cortisol	excess	on	ACC	prognosis	
• Most	 studies	 indicated	 that	 overt	 cortisol	 excess	 is	 associated	 with	 a	 detrimental	prognosis		
• Risk	of	recurrence	after	surgery	is	higher	for	cortisol-secreting	ACC		
• Comorbidities	 associated	 to	 Cushing	 decrease	 life	 expectancy	 and	 complicate	management	of	ACC	patients	
TREATMENT	The	 therapeutic	 approach	 in	 ACC	 varies	 according	 with	 the	 stage	 at	 diagnosis	 and	performance	status.	Surgery	is	the	main	option	in	ACC	without	evidence	of	metastatic	disease	(stages	I–III)	and	the	only	possibility	of	cure:	when	a	radical	resection	is	feasible,	the	5-year	survival	rate	is	approximately	55%26.	Surgery	also	has	a	role	in	the	management	of	stage	IV	ACC,	 provided	 the	metastatic	 spread	 is	 confined	 to	 a	 single	 organ	 and	 can	 be	 treated	with	radical	 intent27.	 The	 role	 of	 tumor	 debulking	 is	 disputed	 and	 this	 approach	 is	 now	 rarely	employed;	however,	it	may	have	an	indication	in	case	of	severe	hypercortisolemia	to	reduce	the	mass	of	secreting	cells3,4,48.		Surgery	for	ACC	consists	of	adrenalectomy,	which	is	performed	by	open	approach	in	patients	with	infiltrative	tumors	or	invasion	of	lymph	nodes.	On	the	other	hand,	stage	I-II	localized	ACC	can	 be	 removed	 by	 either	 laparoscopic	 or	 open	 adrenalectomy3,9.	 Whatever	 the	 surgical	approach,	surgery	must	be	performed	by	an	extremely	skilled	surgical	team,	in	centers	with	high	volume	of	adrenalectomies	per	year28,	with	 the	goal	of	a	R0	resection	(microscopically	free	 margins).	 A	 radical	 resection	 induces	 temporary	 cortisol	 deficiency	 in	 patients	 with	cortisol-secreting	ACC,	who	require	glucocorticoid	replacement	postoperatively.	This	 is	also	the	case	after	removal	of	a	tumor	causing	autonomous	cortisol	secretion	in	patients	without	overt	Cushing	features7.	The	risk	for	recurrence	is	 lower	for	patients	who	undergo	surgery	by	expert	surgeons29	but	cannot	be	not	prevent	 completely	prevented.	More	 than	50%	of	 the	 tumors	 that	have	been	completely	 extirpated	 are	 doomed	 to	 relapse30	 and	 most	 patients	 with	 ACC	 recurrence	experience	further	tumor	progression	and	eventually	die	of	the	disease.	These	outcomes	and	the	significant	propensity	of	ACC	to	recur	provide	a	rationale	for	adjuvant	therapies.		Mitotane	(o,p’-DDD,	an	isomer	of	the	insecticide	dichlorodiphenyltrichloroethane	-	DDT),	is	an	orally	 administered	 adrenolytic	 drug.	 The	 first	 report	 of	 the	 destruction	 of	 the	 zona	
fasciculata	and	zona	reticularis	in	the	adrenal	gland	of	dogs	receiving	mitotane	was	written	in	1960	and	demonstrated	a	marked	reduction	of	glucocorticoids	and	17-hydroxycorticosteroids	in	basal	conditions	and	after	ACTH	stimulation31.	Following	this	observation,	it	was	found	that	mitotane	 is	 able	 to	 inhibit	 gene	 expression	 of	 a	 variety	 of	 cytochrome	 P450-dependent	mitochondrial	 enzymes	 of	 the	 steroidogenetic	 pathway,	 including	 20,22	 desmolase	(CYP11A1),	11β-hydroxylase	(CYP11B1)	and	18β-hydrolase	(CYP11B2)32.	Critical	steps	of	the	inhibitory	effects	on	steroidogenesis	may	occur	in	mitochondria	possibly	involving	CYP11A1,	a	mitochondrial	 enzyme	 that	 catalyzes	 the	 transformation	of	 cholesterol	 to	pregnenolone33.	The	net	effect	 is	an	 inhibition	of	adrenal	 steroid	production;	 thus,	mitotane	may	ameliorate	signs	and	symptoms	of	cortisol	excess,	and	for	this	reason	this	adrenolytic	drug	has	been	used	as	a	medical	treatment	of	all	causes	of	Cushing’s	syndrome34.	Although	 randomized	 controlled	 trials	 on	 the	 use	 of	 adjuvant	 mitotane	 in	 ACC	 patients	following	 radical	 surgery	 are	 still	 unavailable,	 a	 large	 retrospective	 case-control	 study	reported	that	patients	treated	with	adjuvant	mitotane	had	a	significantly	 longer	recurrence-free	 survival	 and	 overall	 survival	 compared	 with	 two	 independent	 groups	 of	 patients	 left	untreated	 following	surgery35.	Recently,	 the	same	group	has	updated	 the	 follow-up	of	 these	cohorts	of	patients	with	almost	10	years	of	additional	observation,	confirming	that	adjuvant	mitotane	 treatment	 is	 associated	 with	 a	 significant	 benefit	 in	 terms	 of	 recurrence-free	survival	regardless	of	 the	hormone	secretory	status36.	 In	 this	study,	median	recurrence-free	survival	was	of	42	months	in	the	adjuvant	group	compared	with	17	months	in	control	group	1	(p<0.001)	and	26	months	control	group	2	(p<0.005)36.	Despite	 its	retrospective	nature,	 this	study	remains	the	most	informative	positive	study	on	the	topic	and	represents	a	reference	for	decision	 making	 on	 adjuvant	 therapy.	 However,	 literature	 is	 conflicting	 and	 there	 is	 also	evidence	 of	 a	 relative	 ineffectiveness	 of	 adjuvant	 mitotane.	 A	 recent	 multicenter	 study	concluded	that	adjuvant	mitotane	was	associated	with	decreased	recurrence-free	survival	and	
overall	survival.	However,	patients	treated	with	mitotane	had	worse	prognostic	factors	than	untreated	patients	(more	stage	IV	and	more	secreting	ACCs	in	the	mitotane	group)37.		During	the	60s	and	70s,	mitotane	was	used	for	the	treatment	of	patients	with	non-operable	ACC,	with	evidence	of	 reduction	of	 the	 tumor	mass	and	 control	of	 the	 symptoms	 related	 to	hormonal	 hypersecretion.	 However,	 despite	 some	 isolated	 cases	 of	 complete	 tumor	regression38,	most	patients	showed	only	a	partial	and	 transient	 response39.	 In	1982,	 for	 the	first	 time,	 Schteingart	 and	 colleagues40	 proposed	 to	 extend	 treatment	 with	 mitotane	 to	patients	 who	 had	 undergone	 complete	 resection	 of	 the	 mass,	 but	 with	 a	 high	 risk	 of	recurrence,	 introducing	 the	 concept	 of	 adjuvant	 treatment.	 In	 2012,	 the	 ESMO	 guidelines	recommended	 the	 use	 of	 mitotane	 after	 surgery	 in	 patients	 with	 ACC	 at	 high	 risk	 of	recurrence,	defined	as	stage	III,	or	Ki-67	>10%,	or	R1	or	Rx	resection.	For	patients	at	low	risk,	characterized	by	stage	I	or	II,	Ki-67	<10%,	and	R0	resection,	adjuvant	therapy	with	mitotane	is	not	mandatory.	An	international,	multi-center,	prospective,	randomized	trial	(ADIUVO	trial)	is	currently	enrolling	low-risk	ACC	patients,	who	are	randomized	to	mitotane	or	observation,	in	order	to	establish	the	efficacy	of	adjuvant	mitotane	in	this	cohort	of	patients41.	In	patients	with	inoperable	or	metastatic	disease,	mitotane	is	the	mainstay	of	treatment	and	can	be	used	as	a	single	agent	or	in	combination	with	classic	cytostatic	drugs.	A	key	concept	of	mitotane	 treatment	 in	patients	with	advanced/metastatic	ACC	 is	 that	disease	 responses	are	mainly	confined	 in	patients	whose	plasma	mitotane	concentrations	are	ranging	between	14	and	20	mg/L42,43.	The	concept	of	a	 therapeutic	 range	has	been	validated	more	recently	 in	a	retrospective	series	of	91	patients	receiving	mitotane	for	unresectable	or	metastatic	ACC44.	In	this	 study,	 mitotane	 level	 above	 14	mg/L	 was	 associated	 with	 tumor	 response	 and	 better	survival	 irrespective	 of	 whether	 mitotane	 was	 administered	 as	 monotherapy	 or	 in	combination	 with	 chemotherapy.	 Owing	 to	 the	 latency	 to	 attain	 the	 therapeutic	 range,	mitotane	monotherapy	is	indicated	in	the	management	of	patients	with	a	low	tumor	burden	
and	 less	 rapid	 disease.	 For	 ACC	 showing	 an	 aggressive	 course	 of	 disease	 or	 with	 many	metastatic	 sites,	 cytotoxic	 chemotherapy	 is	 usually	 recommended.	 Chemotherapy	 in	association	with	mitotane	is	also	reserved	for	patients	with	advanced	ACC	at	diagnosis	or	in	patients	 whose	 disease	 is	 progressing	 on	 mitotane	 therapy,	 when	 mitotane	 is	 usually	maintained,	 if	 tolerated6.	 Studies	 have	 shown	 a	 synergism	 of	 action	 between	mitotane	 and	chemotherapy	due	 to	 its	ability	 to	reverse	multidrug	resistance	mediated	by	P-glycoprotein	expression.	 Overcoming	 multidrug	 resistance	 (MDR)	 gene,	 mitotane	 may	 enhance	 the	cytotoxicity	 of	 anthracyclines,	 etoposide	 and	 taxanes45,46	 whose	 activity	 is	 hampered	 by	enhanced	MDR	gene	expression	by	ACC.		The	management	of	ACC	patients	poses	unique	challenges	to	the	treating	physicians	who	have	to	deal	with	both	oncological	or	endocrinological	issues47.	Hypercortisolism	requires	prompt	treatment	 to	 ensure	 rapid	 correction	 of	 the	 metabolic	 complications	 that	 may	 be	 life	threatening.	A	rapid	control	of	 the	endocrine	syndrome	may	also	 improve	 the	 tolerance	 for	antineoplastic	therapy.	Pertinently,	cortisol-induced	immunosuppression	increases	the	risk	of	severe	infections	during	chemotherapy.	Mitotane	has	a	compelling	indication	in	patients	with	hormone	secreting	ACC,	since	it	has	both	an	inhibitory	effect	on	adrenal	steroidogenesis	and	a	cytotoxic	effect	on	the	tumor,	although	 its	success	rate	 in	controlling	hormone	excess	 is	not	well	known3,10.	Mitotane	is	characterized	by	a	slow	onset	of	action,	 linked	to	the	building	of	adequate	 plasma	 levels,	 which	 means	 treatment	 should	 initially	 include	 rapidly	 effective	steroidogenesis	inhibitors	such	as	metyrapone,	ketoconazole,	etomidate48.	However,	mitotane	is	a	strong	inducer	of	CYP3A4	activity49	and	this	may	cause	drug	interactions	when	used	in	a	combination	 therapy.	The	safety	profile	of	 the	accompanying	drugs	should	also	be	carefully	considered	to	avoid	cumulative	toxicity	with	mitotane	(i.e.	gastrointestinal	and	liver	toxicity).	A	series	of	14	patients	with	severe	hypercortisolism,	including	8	ACC,	have	been	treated	with	a	 combination	of	metyrapone	and	ketoconazole	 in	 two	 tertiary-care	university	hospitals.	 In	
patients	with	ACC,	median	UFC	after	1	week	of	 treatment	 fell	 from	16.0	 to	1.0	ULN	 (upper	limit	of	the	normal	range)	and	after	1	month	UFC	values	were	normal	in	86%	of	patients.	Also	important	 improvements	 of	 clinical	 status,	 potassium,	 glycemia	 and	 blood	 pressure	 were	reported,	with	decrease	in	drugs	used	for	co-morbidities.	Side	effects	were	minimal	and	only	one	 patient	 with	 ACC	 had	 an	 increase	 in	 plasma	 transaminase,	 necessitating	 ketoconazole	withdrawal50.		Recently,	Claps	and	colleagues51	reported	three	cases	of	advanced	ACC	patients	with	Cushing’	s	 syndrome	 treated	with	 a	 combination	 of	metyrapone	with	 the	 regimen	 EDP-M,	 including	etoposide,	 doxorubicin,	 cisplatin	 and	 mitotane.	 EDP-M	 represents	 the	 current	 standard	 of	chemotherapy	 treatment	 for	 advanced	 ACC52.	 Metyrapone	 is	 an	 adrenolytic	 molecule	targeting	 the	 11-beta-hydroxylase	 that	 is	 currently	 used	 to	 treat	 Cushing's	 syndrome	 of	different	 etiologies53.	 The	 drug	 inhibits	 the	 conversion	 of	 11-deoxycortisol	 into	 cortisol	obtaining	 the	 reduction	 of	 cortisol	 synthesis	 within	 2	 hours	 after	 the	 first	 drug	administration54.	 Metyrapone	 metabolism	 and	 elimination	 are	 not	 altered	 by	 concomitant	mitotane.	Indeed,	metyrapone	is	mainly	metabolized	by	hepatic	reduction;	then,	metyrapone	and	reduced	metyrapone	are	then	conjugated	to	the	corresponding	glucuronides	and	nearly	40%	of	the	administered	dose	is	excreted	in	the	urine	within	2	days.	Metyrapone	per	se	does	not	have	antineoplastic	activity48,53.	In	this	study,	the	addition	of	metyrapone	to	EDP-M	led	to	a	 rapid	 resolution	 of	 symptoms	 and	 signs	 of	 Cushing's	 syndrome	 and	 a	 significant	improvement	 of	 the	 patient	 conditions.	 This	 finding	 has	 to	 be	 underlined	 because	 EDP-M	usually	requires	several	weeks	to	attain	a	control	of	hypercortisolism.	Metyrapone	was	well	tolerated,	did	not	increase	the	toxicity	of	the	EDP-M	regimen,	and	did	not	alter	EDP-M	efficacy	in	 terms	of	 tumor	control.	Therefore,	 this	 combination	may	represent	a	 rapid,	effective	and	well-tolerated	treatment	of	overt	Cushing	sustained	by	ACC.		Because	 of	 the	 adrenolytic	 effect	 of	 mitotane,	 all	 patients	 should	 receive	 glucocorticoid	
replacement	 to	 prevent	 adrenal	 insufficiency.	 Steroid	 doses	 are	 typically	 higher	 than	 in	Addison’s	disease,	due	to	an	enhanced	metabolic	clearance	rate	of	glucocorticoids	induced	by	mitotane3,4.	 It	 was	 calculated	 that	 mitotane	 is	 able	 to	 inactivate	 50%	 of	 administered	hydrocortisone	 through	 enhanced	 CYP3A	 enzyme	 activity55.	 An	 inadequate	 treatment	 of	adrenal	 insufficiency	 increases	 mitotane-related	 toxicity,	 particularly	 gastrointestinal	 side	effects,	 and	 reduces	 tolerance56.	Mineralocorticoid	 supplementation	 is	 not	mandatory	 in	 all	patients	because	the	zona	glomerulosa	is	partly	spared	by	the	toxic	effect	of	mitotane	56.		
Conclusions	Adrenocortical	 carcinoma	may	 present	 frequently	with	 Cushing’s	 syndrome	 that	may	 have	atypical	features.	Cushing’s	syndrome	is	ACTH-independent	and	the	concomitance	of	cortisol	and	androgen	excess	is	a	clue	to	suspect	the	diagnosis.	When	an	adrenocortical	carcinoma	is	associated	 with	 cortisol	 excess	 its	 prognosis	 is	 worse	 compared	 to	 non-secretory	 tumors,	even	if		complete	resection	is	attained.	Tumors	causing	hypercortisolism	have	a	higher	risk	of	recurrence.	Moreover,	Cushing’s	syndrome	carries	a	huge	disease	burden	in	case	of	advanced	adrenocortical	 carcinoma	 and	 complicates	 management.	 Controlling	 cortisol	 excess	 is	 an	urgent	need	that	may	be	accomplished	before	giving	chemotherapy	to	overcame	the	enhanced	risk	 of	 infections.	 Mitotane	 is	 the	 mainstay	 of	 medical	 treatment	 of	 hypercortisolism;	however,	 its	 delayed	 action	 calls	 for	 associating	 more	 rapid	 agents.	 The	 inhibitor	 of	steroidogenesis	metyrapone	has	been	used	successfully	in	this	contest.						
Box	3.	Therapy	for	ACC	with	hypercortisolemia	
• Surgery	 is	 the	 treatment	 of	 choice	 of	 ACC	 when	 radical	 resection	 is	 feasible	 and	 is	associated	with	improved	oncological	and	endocrinological	outcomes	
• Despite	radical	surgery,	ACC	has	a	high	recurrence	rate	and	mitotane	is	frequently	used	as	a	post-operative	adjunctive	treatment	
• Advanced	 or	 inoperable	 ACC	 is	 treated	 with	 mitotane	 alone	 or	 in	 combination	 with	chemotherapy	depending	on	patient	and	tumor	characteristics	
• Mitotane	is	the	medical	treatment	of	choice	of	Cushing’s	syndrome	associated	to	ACC	but	combination	with	steroidogenesis	inhibitors	with	more	rapid	onset	of	action	is	initially	required	
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Figure	Legends	
	
Figure	1.	Hormonal	secretion	in	patients	with	ACC	(S.	Luigi	series).	
	
Figure	2.	CT	scan	of	an	adrenocortical	carcinoma	showing	a	large	left	adrenal	mass	of	irregular	shape	and	heterogeneous	density.	
	
Figure	3.	Recurrence	free	survival	in	patients	with	cortisol-secreting	ACC	versus	patients	with	non-functioning	ACC	(S.	Luigi	series).	
 
